Search | Clinical Trials Finder

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine, Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed, Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel, Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 25
States / cities: Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more

Conditions: Carcinoma, Small Cell Lung
Interventions: RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide; Combination Product · Drug
Lead sponsor: EpicentRx, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 18
States / cities: Denver, Colorado • Orange City, Florida • Orlando, Florida + 15 more

Conditions: Recurrent Endometrial Cancer
Interventions: Pembrolizumab, Lenvatinib; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Non Small Cell Lung Cancer
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 51
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 41 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Nivolumab, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo, Docetaxel; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Tampa, Florida • Atlanta, Georgia • Augusta, Georgia + 11 more

Conditions: Lung Neoplasm Malignant
Interventions: Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, Pemetrexed, Sacituzumab tirumotecan, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Carboplatin, Pembrolizumab (adjuvant), Paclitaxel, Steroid mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 9
States / cities: Daphne, Alabama • Santa Barbara, California • Lone Tree, Colorado + 5 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: pembrolizumab/vibostolimab, durvalumab, cisplatin, pemetrexed, etoposide, carboplatin, paclitaxel, thoracic radiotherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Hollywood, Florida + 18 more

Conditions: Advanced Non-small Cell Lung Cancer
Interventions: REGN2810, Platinum-doublet chemotherapy; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: R-DXd, Bevacizumab, Carboplatin, Paclitaxel, Gemcitabine, Pegylated liposomal doxorubicin (PLD); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Fountain Valley, California • Orlando, Florida

Conditions: Non-small Cell Lung Cancer
Interventions: Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 24
States / cities: Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 86
States / cities: Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 68 more

Conditions: Non-small Cell Lung Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more

Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
Interventions: Biospecimen Collection, Cabozantinib, Fluoropyrimidine, Ipilimumab, Nivolumab, Platinum Compound, Platinum Doublet; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 51
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 51
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more

Conditions: Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
Interventions: olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar); Biological · Drug
Lead sponsor: Genelux Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 33
States / cities: Mobile, Alabama • Tucson, Arizona • Duarte, California + 28 more

Conditions: Non-Small Cell Lung Cancer, Solid Tumor
Interventions: Atezolizumab, Standard of Care Chemotherapy, Tiragolumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 7
States / cities: Fort Myers, Florida • St. Petersburg, Florida • Tallahassee, Florida + 4 more

Conditions: Solid Tumors
Interventions: Avelumab; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 53
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 45 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey

Conditions: KRAS P.G12C
Interventions: D3S-001, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Cetuximab; Drug
Lead sponsor: D3 Bio (Wuxi) Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Orange, California • Palo Alto, California • Denver, Colorado + 4 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay; Drug · Other
Lead sponsor: Razor Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 18
States / cities: Mission Viejo, California • Sacramento, California • Santa Rosa, California + 15 more

Conditions: Resectable Non-small Cell Lung Cancer
Interventions: Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Clermont, Florida • Chicago, Illinois • Westwood, Kansas + 5 more

Search by objective public record fields.

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery